News
Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results